Use: Labeled indications
- Cefepime for Injection is a cephalosporin antibacterial indicated for the treatment of the following infections caused by susceptible strains of the designated microorganisms: Pneumonia.
- Empiric therapy for febrile neutropenic patients.
- Uncomplicated and complicated urinary tract infections (including pyelonephritis).
- Uncomplicated skin and skin structure infections.
- Complicated intra-abdominal infections (used in combination with metronidazole) in adults.
- To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefepime for Injection and other antibacterial drugs, Cefepime for Injection should be used only to treat or prevent infections that…
Full indications and usage US FDA label
1 INDICATIONS AND USAGE Cefepime for Injection is a cephalosporin antibacterial indicated for the treatment of the following infections caused by susceptible strains of the designated microorganisms: Pneumonia. (1.1) Empiric therapy for febrile neutropenic patients. (1.2) Uncomplicated and complicated urinary tract infections (including pyelonephritis).
(1.3) Uncomplicated skin and skin structure infections. (1.4) Complicated intra-abdominal infections (used in combination with metronidazole) in adults. (1.5) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefepime for Injection and other antibacterial drugs, Cefepime for Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.
(1.6) 1.1 Pneumonia Cefepime for Injection is indicated in the treatment of pneumonia (moderate to severe) caused by susceptible strains of Streptococcus pneumoniae, including cases associated with concurrent bacteremia, Pseudomonas aeruginosa, Klebsiella pneumoniae, or Enterobacter species. 1.2 Empiric Therapy for Febrile Neutropenic Patients Cefepime for Injection as monotherapy is indicated for empiric treatment of febrile neutropenic patients. In patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate.
Insufficient data exist to support the efficacy of cefepime monotherapy in such patients [see Clinical Studies (14.1)]. 1.3 Uncomplicated and Complicated Urinary Tract Infections (including pyelonephritis) Cefepime for Injection is indicated in the treatment of uncomplicated and complicated urinary tract infections (including pyelonephritis) caused by susceptible isolates of Escherichia coli or Klebsiella pneumoniae, when the infection is severe, or caused by Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis, when the infection is mild to moderate, including cases associated with concurrent bacteremia with these bacteria. 1.4 Uncomplicated Skin and Skin Structure Infections Cefepime for Injection is indicated in the treatment of uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes. 1.5 Complicated Intra-abdominal Infections (used in combination with metronidazole) Cefepime for Injection is indicated in the treatment of complicated intra-abdominal infections (used in combination with metronidazole) in adults caused by susceptible isolates of Escherichia coli, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Enterobacter species, or Bacteroides fragilis [see Clinical Studies (14.2)]. 1.6 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefepime for Injection and other antibacterial drugs, Cefepime for Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.
In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Contraindications
- Immediate hypersensitivity to cefepime, cephalosporins, penicillins or other beta-lactams
Contraindications (US label) US FDA label
4 CONTRAINDICATIONS Cefepime for injection is contraindicated in patients who have shown immediate hypersensitivity reactions to cefepime or the cephalosporin class of antibacterial drugs, penicillins or other beta-lactam antibacterial drugs. Patients with known immediate hypersensitivity reactions to cefepime or other cephalosporins, penicillins or other beta-lactam antibacterial drugs. (4)
Dosing: Adult
- Moderate to severe pneumonia: 1 to 2 g IV every 8 to 12 hours (P. aeruginosa: 2 g every 8 hours)
- Empiric therapy, febrile neutropenia: 2 g IV every 8 hours
- Mild to moderate urinary tract infection: 0.5 to 1 g IV or IM every 12 hours
- Severe urinary tract infection: 2 g IV every 12 hours
- Skin and skin structure infection: 2 g IV every 12 hours
- Complicated intra-abdominal infection (with metronidazole): 2 g IV every 8 to 12 hours
- CrCl 60 mL/min or less: See kidney table: same first dose, then reduced maintenance by CrCl
- § For Pseudomonas aeruginosa, use 2 g IV every 8 hours. (2.1)
- * Or until resolution of neutropenia. (2.1)
- ** Intramuscular route of administration is indicated only for mild to moderate, uncomplicated or complicated UTIs due to E. coli. (2.1)
- Recommended Dosage in Adults with Creatinine Clearance (CrCL) Greater Than 60 mL/min (2.1)
- Site and Type of Infection Dose Frequency Duration (days) Moderate to Severe Pneumonia § 1 to 2 g IV Every 8 to 12 hours 10 Empiric Therapy for Febrile Neutropenic Patients 2 g IV Every 8 hours 7* Mild to Moderate Uncomplicated or Complicated Urinary Tract Infections 0.5 to 1 g IV/IM** Every 12 hours 7 to 10 Severe Uncomplicated or Complicated Urinary Tract Infections 2 g IV Every 12 hours 10 Moderate to Severe Uncomplicated Skin and Skin Structure Infections 2 g IV Every 12 hours 10 Complicated Intra-abdominal Infections § (used in combination with metronidazole) 2 g IV Every 12 hours 7 to 10 Pediatric Patients (2 months to 16 years) Recommended dosage in pediatric with CrCL greater than 60 mL/min. (2.2)
- The usual recommended dosage in pediatric patients is 50 mg per kg per dose administered every 12 hours (every 8 hours for febrile neutropenia). (2.2)
- Patients with Renal Impairment: Adjust dose in patients with CrCL less than or equal to 60 mL/min. (2.3)
2.1 Dosage for Adults
2.1 Dosage for Adults The recommended adult dosages and routes of administration are outlined in Table 1 below for patients with creatinine clearance greater than 60 mL/min. Administer cefepime for injection intravenously over approximately 30 minutes. Table 1: Recommended Dosage Schedule for Cefepime for Injection in Adult Patients with Creatinine Clearance (CrCL) Greater Than 60 mL/min * or until resolution of neutropenia.
In patients whose fever resolves but who remain neutropenic for more than 7 days, the need for continued antimicrobial therapy should be re-evaluated frequently. ** Intramuscular route of administration is indicated only for mild to moderate, uncomplicated or complicated UTIs due to E. coli. § For P. aeruginosa, use 2 g IV every 8 hours. Site and Type of Infection Dose Frequency Duration (days) Adults Intravenous (IV)/ Intramuscular (IM) Moderate to Severe Pneumonia § 1 to 2 g IV Every 8 to 12 hours 10 Empiric therapy for febrile neutropenic patients 2 g IV Every 8 hours 7* Mild to Moderate Uncomplicated or Complicated Urinary Tract Infections, including pyelonephritis 0.5 to 1 g IV/IM** Every 12 hours 7 to 10 Severe Uncomplicated or Complicated Urinary Tract Infections, including pyelonephritis 2 g IV Every 12 hours 10 Moderate to Severe Uncomplicated Skin and Skin Structure Infections 2 g IV Every 12 hours 10 Complicated Intra-abdominal Infections § (used in combination with metronidazole) 2 g IV Every 8 to 12 hours 7 to 10
2.2 Pediatric Patients (2 months up to 16 years)
2.2 Pediatric Patients (2 months up to 16 years) The maximum dose for pediatric patients should not exceed the recommended adult dose. The usual recommended dosage in pediatric patients up to 40 kg in weight for durations as given above for adults is: 50 mg per kg per dose, administered every 12 hours for uncomplicated and complicated urinary tract infections (including pyelonephritis), uncomplicated skin and skin structure infections, and pneumonia (see below).
For moderate to severe pneumonia due to P. aeruginosa give 50 mg per kg per dose, every 8 hours. 50 mg per kg per dose, every 8 hours for febrile neutropenic patients.
2.3 Dosage Adjustments in Patients with Renal Impairment Adult
2.3 Dosage Adjustments in Patients with Renal Impairment Adult Patients Adjust the dose of cefepime for injection in patients with creatinine clearance less than or equal to 60 mL/min to compensate for the slower rate of renal elimination. In these patients, the recommended initial dose of cefepime for injection should be the same as in patients with CrCL greater than 60 mL/min except in patients undergoing hemodialysis.
The recommended doses of cefepime for injection in patients with renal impairment are presented in Table 2. When only serum creatinine is available, the following formula (Cockcroft and Gault equation) 1 may be used to estimate creatinine clearance. The serum creatinine should represent a steady state of renal function: Females: 0.85 x above value Table 2: Recommended Dosing Schedule for Cefepime for Injection in Adult Patients with Creatinine Clearance Less Than or Equal to 60 mL/min *On hemodialysis days, cefepime should be administered following hemodialysis.
Whenever possible, cefepime should be administered at the same time each day. Creatinine Clearance (mL/min) Recommended Maintenance Schedule Greater than 60 500 mg every 12 hours 1 g every 12 hours 2 g every 12 hours 2 g every 8 hours 30 to 60 500 mg every 24 hours 1 g every 24 hours 2 g every 24 hours 2 g every 12 hours 11 to 29 500 mg every 24 hours 500 mg every 24 hours 1 g every 24 hours 2 g every 24 hours Less than 11 250 mg every 24 hours 250 mg every 24 hours 500 mg every 24 hours 1 g every 24 hours Continuous Ambulatory Peritoneal Dialysis (CAPD) 500 mg every 48 hours 1 g every 48 hours 2 g every 48 hours 2 g every 48 hours Hemodialysis* 1 g on day 1, then 500 mg every 24 hours thereafter 1 g every 24 hours In patients undergoing Continuous Ambulatory Peritoneal Dialysis (CAPD), cefepime for injection may be administered at the recommended doses at a dosage interval of every 48 hours (see Table 2).
In patients undergoing hemodialysis, approximately 68% of the total amount of cefepime present in the body at the start of dialysis will be removed during a 3-hour dialysis period. The dosage of cefepime for injection for hemodialysis patients is 1 g on Day 1 followed by 500 mg every 24 hours for the treatment of all infections except febrile neutropenia, which is 1 g every 24 hours.
Cefepime for injection should be administered at the same time each day and following the completion of hemodialysis on hemodialysis days (see Table 2). Equation Pediatric Patients Data in pediatric patients with impaired renal function are not available; however, since cefepime pharmacokinetics are similar in adults and pediatric patients [see Clinical Pharmacology (12.3)], changes in the dosing regimen proportional to those in adults (see Tables 1 and 2) are recommended for pediatric patients.
2.4 Preparation of Cefepime for Injection for Intravenous Infusion Vials
2.4 Preparation of Cefepime for Injection for Intravenous Infusion Vials Constitute the 1 gram or 2 grams vial, of cefepime for injection with the one of the following diluents: Sterile Water for Injection 0.9% Sodium Chloride Injection 5% Dextrose Injection 0.5% or 1% Lidocaine Hydrochloride Injection Sterile Bacteriostatic Water for Injection with Parabens or Benzyl Alcohol Dilute the reconstituted solution with one of the following compatible infusion solutions prior to intravenous infusion (Refer to Table 3 below for the amount of diluent to be added to each vial and the amount of the reconstituted solution to be withdrawn): 0.9% Sodium Chloride Injection 5% and 10% Dextrose Injection M/6 Sodium Lactate Injection 5% Dextrose and 0.9% sodium Chloride Injection Lactated Ringers and 5% Dextrose Injection Normosol ® -R and Normosol ® -M in 5% Dextrose Injection Parenteral drugs should be inspected visually for particulate matter before administration. If particulate matter is evident in reconstituted fluids, the drug solution should be discarded.
Administer the resulting intravenous infusion over approximately 30 minutes. Intermittent intravenous infusion with a Y-type administration set can be accomplished with compatible solutions. However, during infusion of a solution containing cefepime, it is desirable to discontinue the other solution.
2.5 Preparation of Cefepime for Injection for Intramuscular Administration
2.5 Preparation of Cefepime for Injection for Intramuscular Administration Constitute cefepime for injection vials 1 gram and 2 grams with one of the following diluents: Sterile Water for Injection, 0.9% Sodium Chloride, 5% Dextrose Injection, 0.5% or 1% Lidocaine Hydrochloride, or Sterile Bacteriostatic Water for Injection with Parabens or Benzyl Alcohol. Refer to Table 3 below for the amount of diluent to be added to each vial and the amount of reconstituted volume to be withdrawn.
Parenteral drugs should be inspected visually for particulate matter before administration. If particulate matter is evident in reconstituted fluids, the drug solution should be discarded. Table 3: Preparation of Reconstituted Solutions of Cefepime for Injection Single-Dose Vials for Intravenous (IV)/ Intramuscular (IM) Administration Amount of Diluent to be added (mL) Approximate Cefepime Concentration (mg/mL) Amount of Reconstituted Volume to be Withdrawn (mL) Cefepime vial content 1 g (IV) 10 100 10.5 1 g (IM) 2.4 280 3.6 2 g (IV) 10 160 12.5
2.6 Compatibility and Stability Intravenous
2.6 Compatibility and Stability Intravenous Cefepime for Injection Intravenous Infusion Compatibility Cefepime for injection vials are compatible at concentrations between 1 mg per mL and 40 mg per mL with the following intravenous infusion fluids: 0.9% Sodium Chloride Injection, 5% and 10% Dextrose Injection, M/6 Sodium Lactate Injection, 5% Dextrose and 0.9% Sodium Chloride Injection, Lactated Ringers and 5% Dextrose Injection, Normosol ® -R, and Normosol ® -M in 5% Dextrose Injection. These solutions may be stored up to 24 hours at controlled room temperature 20°C to 25°C (68°F to 77°F) or 7 days in a refrigerator 2°C to 8°C (36°F to 46°F).
Admixture Compatibility Cefepime for injection admixture compatibility information is summarized in Table 4. Table 4: Cefepime Admixture Stability NS = 0.9% Sodium Chloride Injection. D5W = 5% Dextrose Injection. na = not applicable. RT/L = Ambient room temperature and light. Cefepime for injection Concentration Admixture and Concentration Intravenous (IV) Infusion Solutions RT/L (20° to 25°C) Stability Time for Refrigeration (2° to 8°C) 40 mg/mL Amikacin 6 mg/mL NS or D5W 24 hours 7 days 40 mg/mL Ampicillin 1 mg/mL D5W 8 hours 8 hours 40 mg/mL Ampicillin 10 mg/mL D5W 2 hours 8 hours 40 mg/mL Ampicillin 1 mg/mL NS 24 hours 48 hours 40 mg/mL Ampicillin 10 mg/mL NS 8 hours 48 hours 4 mg/mL Ampicillin 40 mg/mL NS 8 hours 8 hours 4 to 40 mg/mL Clindamycin Phosphate 0.25 to 6 mg/mL NS or D5W 24 hours 7 days 4 mg/mL Heparin 10 to 50 units/mL NS or D5W 24 hours 7 days 4 mg/mL Potassium Chloride 10 to 40 mEq/L NS or D5W 24 hours 7 days 4 mg/mL Theophylline 0.8 mg/mL D5W 24 hours 7 days 1 to 4 mg/mL na Aminosyn™ II 4.25% with electrolytes and calcium 8 hours 3 days 0.125 to 0.25 mg/mL na Inpersol™ with 4.25% dextrose 24 hours 7 days Cefepime for Injection Admixture Incompatibility Do not add solutions of cefepime for injection to solutions of ampicillin at a concentration greater than 40 mg per mL, or to metronidazole, vancomycin, gentamicin, tobramycin, netilmicin sulfate, or aminophylline because of potential interaction.
However, if concurrent therapy with cefepime for injection is indicated, each of these antibacterial drugs can be administered separately. Intramuscular Cefepime for Injection Cefepime for injection constituted as directed is stable for 24 hours at controlled room temperature 20ºC to 25ºC (68ºF to 77ºF) or for 7 days in a refrigerator 2ºC to 8ºC (36ºF to 46ºF) with the following diluents: Sterile Water for Injection, 0.9% Sodium Chloride Injection, 5% Dextrose Injection, Sterile Bacteriostatic Water for Injection with Parabens or Benzyl Alcohol, or 0.5% or 1% Lidocaine Hydrochloride.
Intramuscular and Intravenous Cefepime for Injection As with other cephalosporins, the color of cefepime for injection powder, as well as its solutions tend to darken depending on storage conditions; however, when stored as recommended, the product potency is not adversely affected.
Dosing: Altered kidney function
Cefepime is cleared mainly by the kidneys, and its clearance falls in proportion to creatinine clearance (CrCl). The US label keeps the first dose unchanged and reduces maintenance doses when CrCl is 60 mL/min or less, with set regimens for hemodialysis and CAPD. Unadjusted doses in kidney impairment cause neurotoxicity (encephalopathy, myoclonus, seizures, nonconvulsive status epilepticus).
Kidney function measure: Label uses CrCl (mL/min; Cockcroft–Gault); adjust at 60 or less.
Show full dosing details
- CrCl ≥60 mL/min
- CrCl >60: usual dose (label: 500 mg to 2 g every 8 to 12 hours by indication). CrCl of exactly 60: use the 30–60 row.
- CrCl 30–59 mL/min
- CrCl 30–60, by usual regimen: 500 mg q12h → 500 mg q24h; 1 g q12h → 1 g q24h; 2 g q12h → 2 g q24h; 2 g q8h → 2 g q12h. First dose as for normal function (label Table 2).
- CrCl 15–29 mL/min
- CrCl 11–29, by usual regimen: 500 mg q12h → 500 mg q24h; 1 g q12h → 500 mg q24h; 2 g q12h → 1 g q24h; 2 g q8h → 2 g q24h (label Table 2).
- CrCl <15 mL/min (not on dialysis)
- CrCl 11–14: as the 11–29 row. CrCl below 11, by usual regimen: 250 mg, 250 mg, 500 mg or 1 g every 24 hours respectively (label Table 2).
- Hemodialysis (intermittent)
- 1 g on day 1, then 500 mg every 24 hours; for the 2 g every 8 hours regimen (febrile neutropenia) 1 g every 24 hours; give at the same time each day and after hemodialysis on dialysis days (label). A 3-hour session removes about 68% of the drug in the body. Literature option (not label): thrice-weekly after each session, 2 g, 2 g and 2 g (1/1/1.5 g and 1.5/1.5/2 g reported in limited data) (Tsai 2025). Troughs of 22 mg/L or more have been associated with neurotoxicity; stop if encephalopathy or myoclonus appears. These regimens are not weight-adjusted and come mostly from small pharmacokinetic studies; confirm the actual last and next session before each dose. See the site guide Antibiotic Stewardship in Hemodialysis (/guides/antibiotic-stewardship-dialysis.html).
- Peritoneal dialysis
- CAPD: the usual dose every 48 hours (500 mg, 1 g, 2 g or 2 g by regimen) (label Table 2). For PD-associated peritonitis (ISPD 2022): intraperitoneal intermittent 1,000 mg daily; continuous loading dose 500 mg/L, then 125 mg/L in each exchange. Continuous cephalosporin doses may need about 25% more in patients with significant residual kidney function (ISPD 2022).
- CRRT
- Not in label. Li 2020 (Table 3): CVVH ultrafiltration 1,000 mL/h or less, 1 g every 8 hours; 1,500 mL/h or more, 2 g every 8 hours or 1 g every 6 hours; 30 mL/kg/h, 2 g every 8 hours as extended infusion. CVVHD dialysate 20–25 mL/kg/h, load 2 g, then 1.5–1.75 g every 8 hours. CVVHDF combined flow 1,000 mL/h or less, 1 g every 8 hours; 1,500 mL/h or more, 2 g every 8 hours or 1 g every 6 hours.
- Dialyzable? Yes: about 68% removed during a 3-hour hemodialysis (label). For overdose the label advises hemodialysis, not peritoneal dialysis. Protein binding about 20%.
- Monitoring CrCl for dose; neurotoxicity (encephalopathy, myoclonus, seizures, nonconvulsive status epilepticus), mainly with unadjusted doses in kidney impairment; stop cefepime if it occurs (label 5.2). Kidney function with aminoglycosides or loop diuretics.
Children (kidney dosing)
Show full dosing details
- eGFR ≥60
- Usual weight-based dose (CrCl >60) (label).
- eGFR 30–59
- No pediatric data; changes proportional to the adult table are recommended (label).
- eGFR 15–29
- No pediatric data; changes proportional to the adult table are recommended (label).
- eGFR <15 (not on dialysis)
- No pediatric data; changes proportional to the adult table are recommended (label).
- Hemodialysis (intermittent)
- No pediatric data; the label recommends changes proportional to the adult table (which includes hemodialysis). Specialist input.
- Peritoneal dialysis
- No pediatric data; the label recommends changes proportional to the adult table (which includes CAPD). Specialist input.
- CRRT
- No pediatric CRRT data in the cited sources. Specialist input.
Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.
renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.
US label text: Renal impairment US FDA label
2.3 Dosage Adjustments in Patients with Renal Impairment Adult Patients Adjust the dose of cefepime for injection in patients with creatinine clearance less than or equal to 60 mL/min to compensate for the slower rate of renal elimination. In these patients, the recommended initial dose of cefepime for injection should be the same as in patients with CrCL greater than 60 mL/min except in patients undergoing hemodialysis.
The recommended doses of cefepime for injection in patients with renal impairment are presented in Table 2. When only serum creatinine is available, the following formula (Cockcroft and Gault equation) 1 may be used to estimate creatinine clearance. The serum creatinine should represent a steady state of renal function: Females: 0.85 x above value Table 2: Recommended Dosing Schedule for Cefepime for Injection in Adult Patients with Creatinine Clearance Less Than or Equal to 60 mL/min *On hemodialysis days, cefepime should be administered following hemodialysis.
Whenever possible, cefepime should be administered at the same time each day. Creatinine Clearance (mL/min) Recommended Maintenance Schedule Greater than 60 500 mg every 12 hours 1 g every 12 hours 2 g every 12 hours 2 g every 8 hours 30 to 60 500 mg every 24 hours 1 g every 24 hours 2 g every 24 hours 2 g every 12 hours 11 to 29 500 mg every 24 hours 500 mg every 24 hours 1 g every 24 hours 2 g every 24 hours Less than 11 250 mg every 24 hours 250 mg every 24 hours 500 mg every 24 hours 1 g every 24 hours Continuous Ambulatory Peritoneal Dialysis (CAPD) 500 mg every 48 hours 1 g every 48 hours 2 g every 48 hours 2 g every 48 hours Hemodialysis* 1 g on day 1, then 500 mg every 24 hours thereafter 1 g every 24 hours In patients undergoing Continuous Ambulatory Peritoneal Dialysis (CAPD), cefepime for injection may be administered at the recommended doses at a dosage interval of every 48 hours (see Table 2).
In patients undergoing hemodialysis, approximately 68% of the total amount of cefepime present in the body at the start of dialysis will be removed during a 3-hour dialysis period. The dosage of cefepime for injection for hemodialysis patients is 1 g on Day 1 followed by 500 mg every 24 hours for the treatment of all infections except febrile neutropenia, which is 1 g every 24 hours.
Cefepime for injection should be administered at the same time each day and following the completion of hemodialysis on hemodialysis days (see Table 2). Equation Pediatric Patients Data in pediatric patients with impaired renal function are not available; however, since cefepime pharmacokinetics are similar in adults and pediatric patients [see Clinical Pharmacology (12.3)], changes in the dosing regimen proportional to those in adults (see Tables 1 and 2) are recommended for pediatric patients.
8.6 Renal Impairment Adjust the dose of cefepime for injection in patients with creatinine clearance less than or equal to 60 mL/min to compensate for the slower rate of renal elimination [see Dosage Adjustments in Patients with Renal Impairment (2.3)].
Dosing: Pediatric
- Approved ages
- 2 months up to 16 years (label).
- Usual dose
- Up to 40 kg: 50 mg/kg every 12 hours (every 8 hours for febrile neutropenia and P. aeruginosa pneumonia) (label).
- Maximum dose
- Not above the recommended adult dose (label).
Kidney dosing in children: see Dosing: Altered kidney function.
renalcarematters.com, reviewedPediatric use (US label) US FDA label
8.4 Pediatric Use The safety and effectiveness of cefepime in the treatment of uncomplicated and complicated urinary tract infections (including pyelonephritis), uncomplicated skin and skin structure infections, pneumonia, and as empiric therapy for febrile neutropenic patients have been established in the age groups 2 months up to 16 years. Use of cefepime for injection in these age groups is supported by evidence from adequate and well-controlled studies of cefepime in adults with additional pharmacokinetic and safety data from pediatric trials [see Clinical Pharmacology (12.3)].
Safety and effectiveness in pediatric patients below the age of 2 months have not been established. There are insufficient clinical data to support the use of cefepime for injection in pediatric patients for the treatment of serious infections in the pediatric population where the suspected or proven pathogen is H. influenzae type b.
In those patients in whom meningeal seeding from a distant infection site or in whom meningitis is suspected or documented, an alternate agent with demonstrated clinical efficacy in this setting should be used.
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use Of the more than 6400 adults treated with cefepime for injection in clinical studies, 35% were 65 years or older while 16% were 75 years or older. When geriatric patients received the usual recommended adult dose, clinical efficacy and safety were comparable to clinical efficacy and safety in non-geriatric adult patients.
Serious adverse events have occurred in geriatric patients with renal insufficiency given unadjusted doses of cefepime, including life-threatening or fatal occurrences of the following: encephalopathy, myoclonus, and seizures [see Warnings and Precautions (5.2), Adverse Reactions (6.2)]. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function.
Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and renal function should be monitored [see Clinical Pharmacology (12.3), Warnings and Precautions (5.2), Dosage and Administration (2.3)].
Administration
2.1 Dosage for Adults The recommended adult dosages and routes of administration are outlined in Table 1 below for patients with creatinine clearance greater than 60 mL/min. Administer cefepime for injection intravenously over approximately 30 minutes. Table 1: Recommended Dosage Schedule for Cefepime for Injection in Adult Patients with Creatinine Clearance (CrCL) Greater Than 60 mL/min * or until resolution of neutropenia. In patients whose fever resolves but who remain neutropenic for more than 7 days, the need for continued antimicrobial therapy should be re-evaluated frequently. ** Intramuscular route of administration is indicated only for mild to moderate, uncomplicated or complicated UTIs due to E. coli . § For P. aeruginosa , use 2 g IV every 8 hours. Site and Type of Infection Dose Frequency Duration (days) Adults Intravenous (IV)/ Intramuscular (IM) Moderate to Severe Pneumonia § 1 to 2 g IV Every 8 to 12 hours 10 Empiric therapy for febrile neutropenic patients 2 g IV Every 8 hours 7* Mild to Moderate Uncomplicated or Complicated Urinary Tract Infections, including pyelonephritis 0.5 to 1 g IV/IM** Every 12 hours 7 to 10 Severe Uncomplicated or Complicated Urinary Tract Infections, including pyelonephritis 2 g IV Every 12 hours 10 Moderate to Severe Uncomplicated Skin and Skin Structure Infections 2 g IV Every 12 hours 10 Complicated Intra-abdominal Infections § (used in combination with metronidazole) 2 g IV Every 8 to 12 hours 7 to 10
2.4 Preparation of Cefepime for Injection for Intravenous Infusion Vials Constitute the 1 gram or 2 grams vial, of cefepime for injection with the one of the following diluents: Sterile Water for Injection 0.9% Sodium Chloride Injection 5% Dextrose Injection 0.5% or 1% Lidocaine Hydrochloride Injection Sterile Bacteriostatic Water for Injection with Parabens or Benzyl Alcohol Dilute the reconstituted solution with one of the following compatible infusion solutions prior to intravenous infusion (Refer to Table 3 below for the amount of diluent to be added to each vial and the amount of the reconstituted solution to be withdrawn): 0.9% Sodium Chloride Injection 5% and 10% Dextrose Injection M/6 Sodium Lactate Injection 5% Dextrose and 0.9% sodium Chloride Injection Lactated Ringers and 5% Dextrose Injection Normosol ® -R and Normosol ® -M in 5% Dextrose Injection Parenteral drugs should be inspected visually for particulate matter before administration. If particulate matter is evident in reconstituted fluids, the drug solution should be discarded. Administer the resulting intravenous infusion over approximately 30 minutes. Intermittent intravenous infusion with a Y-type administration set can be accomplished with compatible solutions. However, during infusion of a solution containing cefepime, it is desirable to discontinue the other solution.
2.5 Preparation of Cefepime for Injection for Intramuscular Administration Constitute cefepime for injection vials 1 gram and 2 grams with one of the following diluents: Sterile Water for Injection, 0.9% Sodium Chloride, 5% Dextrose Injection, 0.5% or 1% Lidocaine Hydrochloride, or Sterile Bacteriostatic Water for Injection with Parabens or Benzyl Alcohol. Refer to Table 3 below for the amount of diluent to be added to each vial and the amount of reconstituted volume to be withdrawn. Parenteral drugs should be inspected visually for particulate matter before administration. If particulate matter is evident in reconstituted fluids, the drug solution should be discarded. Table 3: Preparation of Reconstituted Solutions of Cefepime for Injection Single-Dose Vials for Intravenous (IV)/ Intramuscular (IM) Administration Amount of Diluent to be added (mL) Approximate Cefepime Concentration (mg/mL) Amount of Reconstituted Volume to be Withdrawn (mL) Cefepime vial content 1 g (IV) 10 100 10.5 1 g (IM) 2.4 280 3.6 2 g (IV) 10 160 12.5
2.6 Compatibility and Stability Intravenous Cefepime for Injection Intravenous Infusion Compatibility Cefepime for injection vials are compatible at concentrations between 1 mg per mL and 40 mg per mL with the following intravenous infusion fluids: 0.9% Sodium Chloride Injection, 5% and 10% Dextrose Injection, M/6 Sodium Lactate Injection, 5% Dextrose and 0.9% Sodium Chloride Injection, Lactated Ringers and 5% Dextrose Injection, Normosol ® -R, and Normosol ® -M in 5% Dextrose Injection. These solutions may be stored up to 24 hours at controlled room temperature 20°C to 25°C (68°F to 77°F) or 7 days in a refrigerator 2°C to 8°C (36°F to 46°F). Admixture Compatibility Cefepime for injection admixture compatibility information is summarized in Table 4 . Table 4: Cefepime Admixture Stability NS = 0.9% Sodium Chloride Injection. D5W = 5% Dextrose Injection. na = not applicable. RT/L = Ambient room temperature and light. Cefepime for injection Concentration Admixture and Concentration Intravenous (IV) Infusion Solutions RT/L (20° to 25°C) Stability Time for Refrigeration (2° to 8°C) 40 mg/mL Amikacin 6 mg/mL NS or D5W 24 hours 7 days 40 mg/mL Ampicillin 1 mg/mL D5W 8 hours 8 hours 40 mg/mL Ampicillin 10 mg/mL D5W 2 hours 8 hours 40 mg/mL Ampicillin 1 mg/mL NS 24 hours 48 hours 40 mg/mL Ampicillin 10 mg/mL NS 8 hours 48 hours 4 mg/mL Ampicillin 40 mg/mL NS 8 hours 8 hours 4 to 40 mg/mL Clindamycin Phosphate 0.25 to 6 mg/mL NS or D5W 24 hours 7 days 4 mg/mL Heparin 10 to 50 units/mL NS or D5W 24 hours 7 days 4 mg/mL Potassium Chloride 10 to 40 mEq/L NS or D5W 24 hours 7 days 4 mg/mL Theophylline 0.8 mg/mL D5W 24 hours 7 days 1 to 4 mg/mL na Aminosyn™ II 4.25% with electrolytes and calcium 8 hours 3 days 0.125 to 0.25 mg/mL na Inpersol™ with 4.25% dextrose 24 hours 7 days Cefepime for Injection Admixture Incompatibility Do not add solutions of cefepime for injection to solutions of ampicillin at a concentration greater than 40 mg per mL, or to metronidazole, vancomycin, gentamicin, tobramycin, netilmicin sulfate, or aminophylline because of potential interaction. However, if concurrent therapy with cefepime for injection is indicated, each of these antibacterial drugs can be administered separately. Intramuscular Cefepime for Injection Cefepime for injection constituted as directed is stable for 24 hours at controlled room temperature 20ºC to 25ºC (68ºF to 77ºF) or for 7 days in a refrigerator 2ºC to 8ºC (36ºF to 46ºF) with the following diluents: Sterile Water for Injection, 0.9% Sodium Chloride Injection, 5% Dextrose Injection, Sterile Bacteriostatic Water for Injection with Parabens or Benzyl Alcohol, or 0.5% or 1% Lidocaine Hydrochloride. Intramuscular and Intravenous Cefepime for Injection As with other cephalosporins, the color of cefepime for injection powder, as well as its solutions tend to darken depending on storage conditions; however, when stored as recommended, the product potency is not adversely affected.
US FDA labelDosage forms
Philippines
- Powder for injection: 1 g, 1 g per vial, 1 mg, 1.0 g, 2 g, 500 mg
- Powder for solution for injection: 1 g, 2 g
- I g per vial powder for injection
- Powder for injection (im/iv: 1 g
Registered products in the Philippines
103 products registered with the Food and Drug Administration (FDA) Philippines list Cefepime as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.
Also registered under: Cefepime (as hydrochloride (1 product) · Cefepime (as Hydrochloride) with Arginine (6 products) · Cefepime (as Hydrochloride) with Argine (1 product). Products registered under these spellings are included in the table and marked.
All registered products103
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
4-Gen 1000Cefepime (as hydrochloride) | 1 g Powder for Injection (IM/IV)USP Type III Colorless Glass Vial with Rubber Stopper and Magenta Flip-Off Seal x 10 mL + FFS Sterile Water for Injection (Box of 1's) | Rx | Inject Care Parenterals Pvt. Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International CorporationTrader: Stallion laboratories Pvt. Ltd. | DRP-3102-04 | Jul 12, 2029 | |
AccepimeCefepime (as hydrochloride) | 1 gm Powder for Injection (I.M./I.V.)15 mL USP Type I transparent plain glass vial with 20 mm grey butyl rubber stopper and aluminum flip-off seal (Box of 1's) | Rx | Medisure Laboratories Pakistan Pvt LtdPakistan | Accesspoint International Trading Inc.Importer: Accesspoint International Trading, Inc. | DRP-14206 | Jul 21, 2028 | |
AlcemaxCefepime (as hydrochloride) | 1 g Powder for Injection (IM/IV)USP Type III Colorless Glass Vial with rubber stopper and magenta flip-off seal x 10 mL + FFS Sterile Water for Injection (Box of 1's) | Rx | Inject Care Parenterals Pvt. Ltd.India | Getz Pharma (Phils.), Inc.Importer: Ambica International CorporationTrader: Stallion laboratories Pvt. Ltd. | DRP-3102-03 | Jul 12, 2029 | |
AltamaxCefepime (as hydrochloride) | 1 g Powder for Injection (I.M./I.V.)20 mL-capacity USP Type I colorless and transparent borosilicate glass vial sealed with chlorobutyl rubber stopper and green flip-off aluminum seal Box of 10's | Rx | Taiwan Biotech Co., Ltd.Taiwan | JustRight Healthcare Inc. | DR-XY43753 | Sep 26, 2029 | |
AxeraCefepime (as hydrochloride) | 1 g Powder for Injection (IM/IV)USP Type I Clear Glass Vial with gray rubber stopper and orange/aluminum flip-off seal x 20 mL (Box of 1's and 10's + plastic tray); USP Type I Clear Glass Vial with gray rubber stopper and alucap orange (bronze) flip-off seal x 20 mL (Box of 1's and 10's + plastic tray) | Rx | PT Darya-Varia Laboratoria TbkIndonesia | UNILAB, Inc. | DR-XY41802 | Mar 14, 2028 | |
AxeraCefepime (as hydrochloride) | 1 g Powder for Injection (IM/IV)USP Type I Clear Glass Vial with gray rubber stopper and orange/aluminum flip-off seal x 20 mL (Box of 1's and 10's + plastic tray); USP Type I Clear Glass Vial with gray rubber stopper and alucap orange (bronze) flip-off seal x 20 mL (Box of 1's and 10's + plastic tray) | Rx | PT Darya-Varia Laboratoria TbkIndonesia | UNILAB, Inc. | DRP-13911 | Mar 14, 2028 | |
AxeraCefepime (as hydrochloride) | 2 g Powder for Injection (IM/IV)USP Type I Clear Glass Vial with gray rubber stopper and orange/aluminum flip-off seal or alucap orange (bronze) flip-off seal (Box of 1's; Box of 10's + plastic tray) | Rx | PT Darya-Varia Laboratoria TbkIndonesia | UNILAB, Inc. | DR-XY41803 | Mar 14, 2028 | |
AxeraCefepime (as hydrochloride) | 2 g Powder for Injection (IM/IV)USP Type I Clear Glass Vial with gray rubber stopper and orange/aluminum flip-off seal or alucap orange (bronze) flip-off seal (Box of 1's; Box of 10's + plastic tray) | Rx | PT Darya-Varia Laboratoria TbkIndonesia | UNILAB, Inc. | DRP-13963 | Mar 14, 2028 | |
AxeraCefepime (as hydrochloride) | 500 mg Powder for Injection (IM/IV)USP Type I Clear Glass Vial with Gray Rubber Stopper and Orange/Aluminum Flip-off Seal or Alucap Orange (Bronze) Flip-off Seal x 10 mL Box of 1's; Box of 10's + Plastic Tray | Rx | PT Darya-Varia Laboratoria TbkIndonesia | UNILAB, Inc. | DR-XY41801 | Mar 14, 2028 | |
BacefimeCefepime (as hydrochloride) | 1g Powder for Injection (IM/IV)Transparent Borosilicate Glass Vial with Butyl Rubber Stopper and Aluminum Flip-Off Cap x l's (Box of 10's) | Rx | NCPC Hebei Huamin Pharmaceutical Company LimitedChina | GPC Geo Pharma Corporation | DRP-10893 | Dec 14, 2026 | |
BizapimeCefepime (as hydrochloride) | 1 g Powder for Injection (IV/IM)20 mL Type I colorless glass vial with grey bromobutyl rubber stopper and green aluminum polypropylene flip-off cap (Box of 10's) | Rx | Laboratorio Reig Jofre S.A.Spain | Penta Labs Australia (Philippines) | DRP-10532 | Oct 14, 2031 | |
BizapimeCefepime (as hydrochloride) | 2 g Powder for Injection (IM/IV)50 mL Type I colorless glass vial with grey bromobutyl rubber stopper and green aluminum polypropylene flip-off cap (Box of 10's) | Rx | Laboratorio Reig Jofre S.A.Spain | Penta Labs Australia (Philippines) | DRP-10533 | Oct 14, 2031 | |
BlefimeCefepime (as Hydrochloride) | 1 g Powder for Injection (I.M./I.V.)USP Type I Clear Glass Vial w/ Grey Butyl Rubber Stopper X 10 mL (Box of 1's) | Rx | NCPC Hebei Huamin Pharmaceutical Co., Ltd.China | Vintel Med EnterprisesImporter: Aglobal Care, Inc. | DRP-5876-01 | Apr 8, 2028 | |
BonpimeCefepime (as hydrochloride) | 1 g Powder for Injection (IM/IV20 mL USP Type III Clear Glass Vial with Grey Bromobutyl Rubber Stopper, Aluminum Seal, and Blue Flip-off Cap (Box of 1's) | Rx | Makcur Laboratories LimitedIndia | Penta Labs Australia (Philippines)Trader: Usquare Lifescience Pvt. Ltd. | DRP-16272 | Jan 17, 2030 | |
CefegenCefepime (as hydrochloride) | 1 g per vial Powder for Injection (IM/IV)USP Type II Clear Glass Vial (Box of 1's) & 2 Ampoules of 5 mL Sterile Water for Injection as diluent | Rx | Neutro Pharma (Pvt.) Ltd.Pakistan | Genzen Pharmaceutical TradingImporter: Raquel-Abbas Pharmaceuticals & General Merchandise | DRP-10462-02 | Mar 3, 2031 | |
1 g Powder for Injection (IM/IV)10 mL-capacity USP Type II clear colorless glass vial With butyl rubber stopper, aluminum seal and blue flip- off cap (Box of 1's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Marcburg Philippines Inc. | DR-XY49490 | Sep 5, 2030 | ||
Cefenova-1000Cefepime (As Hydrochloride) | 1 g Powder For Injection (I.M./I.V.)10 mL USP Type II glass vial with gray butyl rubber stopper, aluminum seal and blue flip-off cap (Box of l's and 10's) | Rx | Reyoung Pharmaceutical Co. Ltd.China | Medinova Pharmaceutical Inc. | DRP-10999 | Dec 31, 2026 | |
CefeproCefepime (as hydrochloride) | 1 g Powder for Injection (IM/IV)15 mL USP Type III glass vial with 20mm grey butyl rubber stopper and 20mm colored flip off aluminum seal (Taxim Blue) (Box of 1’s) | Rx | Sance Laboratories Pvt. Ltd.India | Greencore Pharma Inc. | DRP-18398 | Jun 30, 2031 | |
1 g Powder for Solution for Injection (IM/IV)Store at temperatures not exceeding 30°C. Protect from light. | Rx | Reyoung Pharmaceutical Co., Ltd.China | Sanimed Pharmaceuticals Inc. | DRP-18729 | Aug 27, 2031 | ||
CefesaveCefepime Hydrochloride | 2 g Powder for Injection (I.M./I.V)USP Type I Clear Glass Vial x 20 mL (Box of 1's) | Rx | Yeluri Formulations Pvt. Ltd.India | Savelink Pharma and Trading Co.Importer: Medinova Pharmaceutical Inc. | DRP-3387-04 | Aug 9, 2028 | |
CefevexCefepime | 1g Powder for Injection (IM/IV)Type II Mould Vial (Box of 10's Packed Individually) | Rx | Reyoung Pharmaceutical Co., Ltd.China | SANNOVEX PHARMACEUTICAL DISTRIBUTOR | DR-XY42232 | Jul 15, 2028 | |
CefevexCefepime Hydrochloride | 1g Powder For Solution for Injection (IM/IV)10 mL-capacity clear glass vial with rubber stopper and aluminum plastic cap + clear glass ampoule x 10 mL for sterile water for injection (as diluent) (in one box) 10 mL-capacity clear glass vial with rubber stopper and aluminum plastic cap (Box of 10's) | Rx | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.China | Sannovex Pharmaceutical Distributor | DR-XY49721 | Jun 2, 2031 | |
Ceficad 1000Cefepime (as hydrochloride) | 1g Powder for Injection (IM/IV)USP Type III Flint Glass Vial (Box of 1's) | Rx | Cadila Pharmceuticals LimitedIndia | Importer: BIOCARE LIFESCIENCES, INC. | DRP-12038 | Jun 26, 2029 | |
Cefimed 1000Cefepime(As Hydrochloride) | 1 g Powder for Injection (IM/IV)Type I Flint Glass Vial with Gray Bromobutyl Rubber Stopper and Yellow Aluminum Flip-Off Seal Cap xe l's (Box of 1's) | Rx | Yeluri Formulations Pvt. Ltd.India | Importer: Medinova Pharmaceutical, Inc. | DRP-10889 | Dec 14, 2026 | |
CeflozylCefepime (as hydrochloride) | 1g Powder for Injection (IM/IV)20mL-Capacity Type III Clear Glass Vial Sealed with Gray Bromobutyl Rubber Stopper and Aluminum Seal with Flip-Off Cap x 1mL + 10mL Sterile Water for Injection in Type I Clear Glass Ampoule (Diluent) (Box of 1's) | Rx | Vellinton HealthcareIndia | Pranish Inc. | DR-XY49754 | Jun 18, 2031 | |
Cefpime 1000Cefepime (as hydrochloride with arginine) | 1g Powder for Solution for Injection (IM/IV)20 mL-capacity USP Type III clear glass vial with rubber stopper and aluminum flip-off seal + plastic ampoule x 10 mL for sterile water for injection (diluent) (Box of 1's) | Rx | Innova Captab Ltd.India | Airlife International Trading Corporation | DRP-17516 | Jan 16, 2031 | |
CemoxiCefepime (as hydrochloride) | 2 g Powder for Injection (IM/IV)USP Type I clear glass vial, with grey chlorobutyl rubber stopper, aluminum seal and blue flip-off cap. (Box of 10's) | Rx | Hankook Korus Pharm. Co., Ltd.Korea | H & B Pharma International Inc.Trader: Union Korea Pharm Co., | DRP-16056 | Oct 29, 2029 | |
Centrapime-500Cefepime (as hydrochloride) | 500 mg Powder for Injection (IM/IV)10 mL-capacity USP Type I Clear Glass Vial with Gray Bromobutyl Rubber Stopper (Box of 1's) | Rx | Swiss Parenterals Ltd.India | Central West Medicale Inc.Importer: Medinova Pharmaceutical Inc. | DRP-13431-01 | Feb 17, 2028 | |
CepefilCefepime (as hydrochloride) | 1 g Powder for Injection (IM/IV)USP Type III Colorless Glass Vial with rubber stopper and magenta flip-off seal x 10 mL + FFS Sterile Water for Injection Box of 1's | Rx | Inject Care Parenterals Pvt. Ltd.India | Vintel Med EnterprisesImporter: Ambica International CorporationTrader: Stallion laboratories Pvt. Ltd. | DRP-3102-02 | Jul 12, 2029 | |
CephalexCefepime (as hydrochloride) | 1 g Powder for Injection (IM/IV)15 mL-capacity USP Type I Clear Vial with grey bromobutyl rubber stopper with aluminum flip-off seal and olive green cap (Box of 1's) | Rx | Swiss Parenterals Ltd.India | A-Z Market Enterprise Developers Inc. | DR-XY48160 | Jul 20, 2027 | |
CepimedCefepime (as hydrochloride) | 1 g Powder for Injection (IM/IV)20 mL USP Type III clear and colorless glass vial sealed with bromobutyl rubber stopper and magenta flip-off seal (Box of 1's) | Rx | Zeiss Pharmaceuticals Pvt. Ltd.India | Ranixx PharmaceuticalsImporter: Sanimed Pharmaceuticals Inc. | DRP-7125-03 | Mar 29, 2027 | |
CepiramCefepime (as hydrochloride) | 1 g Powder for Injection (IM/IV)USP Type II Glass Vial with Film-Coated Bromobutyl Rubber Stopper and Aluminum-Plastic Combined Cap x 10 mL (Box of 1's) | Rx | Qilu Pharmaceutical Co. Ltd.China | The Cathay Drug Co., Inc. | DR-XY49120 | Jul 4, 2029 | |
CepiramCefepime (as Hydrochloride) | 1 g Powder for Injection (IM/IV)USP Type III Colorless Glass Vial with rubber stopper and magenta flip-off seal x 10 mL + FFS Sterile Water for Injection (Box of 1's) | Rx | Inject Care Parenterals Pvt. Ltd.India | The Cathay Drug Co., Inc.Importer: Ambica International CorporationTrader: Stallion laboratories Pvt. Ltd. | DRP-3102-06 | Jul 12, 2029 | |
CepiramCefepime (as hydrochloride) | 1 g Powder for Injection (IM/IV)Type I clear and colorless glass vial Box of 1's | Rx | Zeiss Pharmaceuticals Pvt. Ltd.India | The Cathay Drug Co., Inc.Importer: Baxter Healthcare Philippines Inc.Trader: Baxter Pharmaceuticals India Private Limited | DRP-6588-01 | Apr 18, 2028 | |
CyfepimeCefepime (as hydrochloride) | 1 g Powder for Injection (I.M./I.V.)Tubular glass vial, sealed with rubber stopper and capped with aluminum-plastics combination caps in monocarton (Box of 10’s) | Rx | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.China | AMB HK Enterprises Inc. | DRP-8376 | Sep 18, 2029 | |
DecextremeCefepime Hydrochloride | 1 g Powder For Solution For Injection (IM/IV)15 mL-capacity TYpe IIII Glass Vial Sealed with Bromobutyl Rubber Stoppper with Aluminum Seal and Flip-off cap x 1's (Box of 1's) | Rx | Ananta Medicare LimitedIndia | Ambica International Corporation | DRP-18791 | Sep 8, 2031 | |
DecextremeCefepime Hydrochloride | 2 g Powder For Solution For Injection (IM/IV)20 mL -capacity Type III Glass Vial Sealed with Bromobutyl Rubber Stopper with Aluminum Seal and Flip-off Cap x 1's (Box of 1's) | Rx | Ananta Medicare LimitedIndia | Ambica International Corporation | DRP-18792 | Sep 8, 2031 | |
DeltacefCefepime (as hydrochloride) | 1 g Powder for Injection (IM/IV)15 mL-capacity Type I borosilicate clear glass vial with grey bromobutyl rubber stopper and aluminum cap (Box of 1's) | Rx | Medochemie (Far East) Ltd., (Aseptic Cephalosporin Facility)Vietnam | Detoxicare Philippines, Inc. | DRP-11920 | May 20, 2027 | |
DivipimeCefepime (as Hydrochloride) | 1 g Powder for Injection (I.M./I.V.)20 mL-Type I Glass Vial Sealed with Grey Butyl Rubber Plug and Pink Flip Off Seal Cap x 1's (Box of 1's) | Rx | Venus Remedies LimitedIndia | Divjot Enterprises Corp. | DR-XY49188 | Aug 29, 2029 | |
FepimCefepime (as hydrochloride) | 1 g Powder for Injection (IM/IV)USP Type I Clear Colorless Glass Vial Box of 1's | Rx | Yeluri Formulations Pvt. Ltd.India | Labmate Pharma Inc.Importer: Suhitas Pharmaceuticals Inc.Trader: Sherrington Pharmaceuticals Pvt. Ltd. | DRP-3828 | Jul 9, 2027 | |
Fepimed-1Cefepime (as hydrochloride) | 1 g Powder for Injection (IV)10 mL USP Type II Clear Glass Vial with Grey Butyl Rubber Stopper and Blue Flip-Off Cap (Box of 1's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Dreamax Incorporated | DRP-15644 | Aug 14, 2029 | |
Fepimed-1 PlusCefepime (as hydrochloride) | 1 g Powder for Injection (IV)10 mL USP Type II Clear Glass Vial Sealed with Grey Butyl Rubber Stopper and Blue Flip-Off Cap x 1's+ USP Type I Clear Glass Ampoule x 10 mL containing Sterile Water for Injection (as diluent) | Rx | Reyoung Pharmaceutical Co., LtdChina | Dreamax Incorporated | DRP-15772 | Sep 20, 2029 | |
ForcefCefepime (as hydrochloride) | 1 g Powder for Injection (I.M./I.V.)20 mL Capacity USP Type III Clear and Colorless Glass Vial with Grey Bromo Butyl Rubber Stopper and White Colored Flip-off Seal Box of 1's | Rx | Theon Pharmaceuticals LimitedIndia | HEXAGON PHARMACEUTICALS | DR-XY46816 | Jan 24, 2030 | |
GlobalpimeCefepime (As Hydrochloride) | 1.0 g Powder for Injection (I.V./I.M.)USP Type II Colorless and Transparent Glass Vial Sealed with Gray Bromobutyl Rubber Stopper and Aluminum Blue Flip-off Plastic Cap in Monocarton (Box of 10's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | First Global Trading Corporation | DRP-11938 | May 20, 2027 | |
GofimeCefepime (as hydrochloride) | 1g Powder for Injection (I.M./I.V)10 mL USP Type II glass vial with gray butyl rubber stopper, aluminum seal and blue flip-off cap (Box of 1's and 10's) | Rx | Reyoung Pharmaceutical Co. Ltd.China | Applied Pharmaceutical Distribution Inc.Importer: Medinova Pharmaceutical Inc. | DRP-10999-02 | Dec 31, 2026 | |
GofimeCefepime hydrochloride | 2 g Powder for Injection (I.M./I.V)USP Type I Clear Glass Vial x 20 mL (Box of 1's and 10's) | Rx | Yeluri Formulation Pvt. Ltd.India | APPLIED PHARMACEUTICAL DISTRIBUTION INC.Importer: Medinova Pharmaceutical Inc. | DRP-3387-02 | Aug 9, 2028 | |
GofimeCefepime (as hydrochloride) | 2 g Powder for Injection (IM/IV)20 mL-capacity USP Type 1 clear and colorless glass vial (Box of 1's) | Rx | Yeluri Formulations Pvt. LtdIndia | Applied Pharmaceutical Distribution Inc.Importer: Suhitas Pharmaceuticals Inc.Trader: Sherrington Pharmaceuticals Pvt. Ltd. | DRP-3830-01 | Jul 9, 2027 | |
1 g Powder for Injection (I.M./I.V.)1 g vial in individual boxes (Box of 10's) | Rx | Harbin Pharmaceutical Group Co., Ltd General Pharm. FactoryChina | Endure Medical Inc. | DRP-16400 | Jan 18, 2031 | ||
500 mg Powder for Injection (IM/IV)USP Type I Clear vials with rubber stopper and blue flip-off seal individually boxed (Box of 10's) | Rx | Harbin Pharmaceutical Group Co., Ltd. General Pharm. FactoryChina | Endure Medical, Inc. | DR-XY34471 | Apr 18, 2028 | ||
500 mg Powder for Injection (IM/IV)USP Type I Clear vials with rubber stopper and blue flip-off seal individually boxed (Box of 10's) | Rx | Harbin Pharmaceutical Group Co., Ltd. General Pharm. FactoryChina | Endure Medical, Inc. | DRP-16401 | Apr 18, 2028 | ||
IvipimeCefepime (as hydrochloride) | 1 g Powder for Injection (IV)20 mL USP Type I Flint Glass Vial with Grey Rubber Stopper and Aluminum Flip-Off Seal (Box of 1's) | Rx | VHB Medi Sciences LimitedIndia | Bliss Pharma Distribution and Consultancy | DRP-15771 | Sep 20, 2029 | |
LuopimeCefepime (as hydrochloride) | 1 g Powder for Injection (IM/IV)15 mL-capacity Low Borosilicate glass vial sealed with bromobutyl rubber stopper and aluminum-plastic cap in a box | Rx | Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.China | Door 2 Dacota Holdings Inc | DRP-16444 | Mar 13, 2030 | |
MaxefCefepime (as Hydrochloride) | 1 g Powder for Injection (IM/IV)Clear USP Type I Glass Vial x 15mL plus USP Type I Clear Glass Ampoule of Sterile Water for Injection 5 mL (as Diluent) (Box of 1 Vial and 1 Ampoule) | Rx | Geofman PharmaceuticalsKarachi Pakistan | Sahar International Trading Inc. | DRP-7681 | Oct 26, 2031 | |
MedifimeCefepime (as hydrochloride) | 1 g Powder for Injection (IM/IV)20 mL-capacity USP Type III clear glass vial with rubber stopper and aluminum orange flip-off seal and glass ampoule x 10mL (diluent) (Box of 1's) | Rx | Finebiotics Pharma LtdIndia | Medinova Pharmaceuticals Inc. | DRP-16145 | Nov 13, 2029 | |
Medifime-2Cefepime (as Hydrochloride) | 2g Powder for Injection (IM/IV)20 mL-capacity USP Type III glass vial with grey butyl rubber stopper, aluminum seal and green flip-off cap (Box of 1's) | Rx | Ananta Medicare LimitedIndia | Medinova Pharmaceutical Inc | DRP-18521 | Jul 27, 2031 | |
Megapime HospiCefepime (As Hydrochloride) | 1 g Powder for Injection (I.M/I.V)USP Type I Clear Glass Vial w/ Grey Butyl Rubber Stopper and Aluminum Cap with Blue Colored Plastic Flip-off Seal X 10 mL (Box of 1's) | Rx | NCPC HEBEI HUAMIN PHARMACEUTICAL CO., LTD.China | ALKEM LABORATORIES CORPORATIONImporter: AGLOBAL CARE, INC. | DRP-5876-02 | Apr 8, 2028 | |
MofixemCefepime (as hydrochloride) | 1 g Powder for Injection (I.M./I.V.)10-mL transparent and colorless USP type II glass vial sealed with gray halogenated butyl rubber stopper and blue flip-off cap (Box of 10's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Philgen Pharmaceuticals Inc | DRP-15148 | May 14, 2029 | |
MyfepCefepime (as hydrochloride) | 1 g Powder for Injection (IM/IV)20 mL-capacity USP Type III clear and colorless glass vial with grey bromobutyl rubber stopper and aluminum. seal with red flip-off cap (Box of 1's) | Rx | Makcur Laboratories LimitedIndia | Afree Pharmaceutical Distribution Corp. | DRP-14121 | Jun 23, 2028 | |
NeupimeCefepime (as hydrochloride) | I g per vial Powder for Injection (IM/IV)USP Type II Clear Glass Vial (Box o f 1 's) & 2 Ampoules o f 5 mL Sterile Water for Injection as diluent | Rx | Neutro Pharma (Pvt.) Ltd.Pakistan | Raquel-Abbas Pharmaceuticals & General Merchandise | DRP-10462 | Mar 3, 2031 | |
NoneCefepime (as hydrochloride) | 1 g Powder for Injection (IM/IV)USP Type I Clear Glass Vial with gray rubber stopper and orange/aluminum flip-off seal x 20 mL (Box of 1's and 10's + plastic tray) | Rx | PT Darya-Varia Laboratoria TbkIndonesia | RiteMED Phils., Inc.Importer: UNILAB, Inc. | DRP-13911-01 | Mar 14, 2028 | |
NoneCefepime (as hydrochloride) | 1 g Powder for Injection (IM/IV)USP Type III Colorless Glass Vial with Rubber Stopper and Magenta Flip-off Seal x 10 mL + FFS Sterile Water for Injection (Box of 1's) | Rx | Inject Care Parenterals Pvt. Ltd.India | Diafarm Inc.Importer: Ambica International CorporationTrader: Stallion laboratories Pvt. Ltd. | DRP-3102-05 | Jul 12, 2029 | |
NoneCefepime (as hydrochloride) | 2 g Powder for Injection (IM/IV)USP Type I Clear Glass Vial with gray rubber stopper and orange/aluminum flip-off seal or alucap orange (bronze) flip-off seal (Box of 1's; Box of 10's + plastic tray) | Rx | PT Darya-Varia Laboratoria TbkIndonesia | Ritemed Phils., Inc.Importer: UNILAB, Inc. | DRP-13963-01 | Mar 14, 2028 | |
500 mg Powder for Injection (IM/IV)USP Type I Clear vials with rubber stopper and blue flip-off seal individually boxed (Box of 10's) | Rx | Harbin Pharmaceutical Group Co., Ltd. General Pharm. FactoryChina | Phil. Pharmawealth, Inc.Importer: Endure Medical, Inc. | DRP-16401-01 | Apr 18, 2028 | ||
NovafimeCefepime (As Hydrochloride) | 1g Powder For Injection (IM/IV)Type I Clear Glass Vial with Gray Bromobutyl Rubber Stopper and Green Aluminum Flip-Off Seal Cap x l's (Box of l's) | Rx | Swiss Parenterals Ltd.India | Medinova Pharmaceutical, Inc. | DRP-11018 | Jan 18, 2027 | |
NovafimeCefepime (as Hydrochloride) | 500mg Powder for Injection (I.M./I.V.)10 mL-capacity USP Type I Clear Glass Vial with Gray Bromobutyl Rubber Stopper [Box of 1's] | Rx | Swiss Parenterals Ltd.India | Medinova Pharmaceutical Inc. | DRP-13431 | Feb 17, 2028 | |
OfipimeCefepime (as hydrochloride) | 1g Powder for Injection (I.M./I.V.)USP Type III Clear and Colorless Glass Vial x 20mL (Box of 1’s) | Rx | Inject Care Parenterals Pvt. Ltd.India | Orange Biotec, Inc.Importer: Suhitas Pharmaceuticals, Inc.Trader: Mac Heal Laboratories Ltd. | DRP-3266-02 | Sep 21, 2031 | |
OrapimeCefepime (as hydrochloride) | 1 g Powder for Injection (IM/IV)USP Type III Clear and Colorless Glass Vial x 20 mL (Box of 1’s) | Rx | Inject Care Parenterals Pvt. Ltd.India | Orange Biotec Inc.Importer: Suhitas Pharmaceuticals Inc.Trader: Mac Heal Laboratories Ltd. | DRP-3266-01 | Sep 21, 2031 | |
Pime-MaxCefepime (as hydrochloride) | 1 g Powder for Injection (IM/IV)USP Type III Clear Glass Vial + 10 mL USP Type III Clear Ampoule Box of 1 Vial + Diluent | Rx | Zazen Pharma Pvt. Ltd.India | I.E. Medica, Inc.Trader: Stratgen Pharma Pvt. Ltd. | DRP-2222 | Jun 2, 2030 | |
ProcefepCefepime (as hydrochloride) | 1g Powder for Injection (IM/IV)USP Type III clear and colorless glass vial sealed with bromobutyl rubber stopper and magenta flip-off seal x 20mL Box of 1's | Rx | Zeiss Pharmaceuticals Pvt. Ltd.India | Ellebasy Medicale Group Inc.Importer: Sanimed Pharmaceuticals Inc. | DRP-7125-02 | Mar 29, 2027 | |
RovatimCefepime Hydrochloride | 2 g Powder for Injection (I.M./I.V)USP Type I Clear Glass Vial x 20 mL (Box of 1's); USP Type I Clear Glass Vial x 20 mL (Box of 10's) | Rx | Yeluri Formulation Pvt. Ltd.India | Medinova Pharmaceutical Inc. | DRP-3387 | Aug 9, 2028 | |
Sanocef 1000Cefepime (as hydrochloride) | 1 g Powder for Injection (I.M./I.V.)USP Type III clear glass vial with grey butyl rubber stopper and flip off seal Box of 1’s | Rx | Sance Laboratories Pvt. Ltd.India | AMB HK Enterprises Inc. | DRP-8400 | Sep 25, 2029 | |
SanopimeCefepime (as hydrochloride) | 1 g Powder for Injection (IM/IV)20 mL USP Type III clear and colorless glass vial sealed with bromobutyl rubber stopper and magenta flip-off seal (Box of 1's) | Rx | Zeiss Pharmaceuticals Pvt. Ltd.India | Sanimed Pharmaceuticals Inc. | DRP-7125 | Mar 29, 2027 | |
Sanpime 1000Cefepime (as hydrochloride) | 1 g Powder for Injection (IM/IV)20 mL USP Type III clear and colorless glass vial sealed with bromobutyl rubber stopper and magenta flip-off seal (Box of 1's) | Rx | Zeiss Pharmaceuticals Pvt. Ltd.India | Oro Sinai Pharma and General Merchandise, Inc.Importer: Sanimed Pharmaceuticals Inc. | DRP-7125-01 | Mar 29, 2027 | |
SaphipimeCefepime (as hydrochloride) | 1 gram Powder for Injection (I.V./I.M.)USP Type I Flint Glass Vial with Gray Bromo Butyl Rubber Stopper and Aluminum Taxim Blue Flip-off Seal (Box of 1's and 10's) | Rx | Kilitch Drugs (India) Ltd.India | Nelpa Lifesciences, Inc. | DRP-12262 | Jul 6, 2027 | |
Seabact-1000Cefepime Hydrochloride | 1 g Powder for Injection (IV)15mL-capacity Type I Flint Glass Vial Sealed with Grey Butyl Rubber Stopper and Yellow Coloured Flip-off Seal (Box of 1's) | Rx | Yeluri Formulations Pvt. Ltd.India | Seapharma International, Inc. | DRP-11413 | Apr 25, 2027 | |
Seabact-2000Cefepime (as hydrochloride) | 2g Powder for Injection (IV)20mL-capacity Type I Flint Glass Vial with Grey Butyl Rubber Stopper and Green Colored Aluminum Flip-off Seal (Box of 1's) | Rx | Yeluri Formulations Pvt. Ltd.India | Seapharma International, Inc. | DRP-11412 | Apr 25, 2027 | |
Sefepi 1000Cefepime (as Hydrochloride) | 1 g Powder for Injection (I.M./I.V.)USP Type III glass vial x 20 mL (Box of 1’s) | Rx | Sakar Healthcare Pvt. Ltd.India | Macropharma Corporation | DRP-12461 | Aug 11, 2027 | |
SefepimCefepime (as hydrochloride) | 1 g Powder for Injection (IM/IV)15 mL USP Type I clear glass vial+ 10 mL ampoule of Sterile Water for Injection as diluent per box | Rx | Nectar Lifesciences LimitedIndia | Hovid Inc.Trader: Hovid Berhad | DR-XY46197 | Dec 13, 2027 | |
SefpimeCefepime | 1g Powder for InjectionUSP Type I Glass Vial Packed in Monocarton x 15mL (Box of 10's) | Rx | Sinopharm Zhijun (Shenzhen) Pharmaceutical Co., Ltd.China | Dynasty Pharmaceuticals | DRP 8489 | Jun 23, 2031 | |
SefpimeCefepime (as hydrochloride) | 2g Powder for Injection (I.V./I.M.)30mL - capacity Type III Clear and Colorless Glass Vial with Chlorobutyl Rubber Stopper and Aluminum Seal with Red Flip-off cap (Box of 10 vials in Individual cartons) | Rx | Sinopharm Zhijun (Shenzhen) Pharmaceutical Co., Ltd.China | Dynasty Pharmaceuticals | DRP-10023 | Nov 21, 2027 | |
SepimeCefepime (as hydrochloride) | 1 g Powder for Injection (I.M/I.V)USP Type I Clear Glass Vial w/ Grey Butyl Rubber Stopper and Aluminum Cap with Blue Colored Plastic Flip-off Seal X 10 mL (Box of 1's) | Rx | NCPC HEBEI HUAMIN PHARMACEUTICAL CO., LTD.China | AGLOBAL CARE, INC. | DRP-5876 | Apr 8, 2028 | |
Sherpime-1000Cefepime (as Hydrochloride) | 1g Powder for Injection (IM/IV)Type I Flint Glass Vial Sealed with Grey Butyl Rubber Stopper and Yellow Colored Flip-off Seal (Box of 10's) (Box of 10's) | Rx | Yeluri Formulations Pvt. Ltd.India | Pharma-Surrey International, Inc. | DRP-9150 | Sep 18, 2030 | |
SolpimeCefepime (as hydrochloride) | 1 g Powder for Injection (I.M/I.V)USP Type I Clear Glass Vial w/ Grey Butyl Rubber Stopper and Aluminum Cap with Blue Colored Plastic Flip-off Seal X 10 mL (Box of 1's) | Rx | NCPC Hebei Huamin Pharmaceutical Co., Ltd.China | Solvire Life IncorporatedImporter: Aglobal Care, Inc. | DRP-5876-03 | Apr 8, 2028 | |
SpectraxCefepime (as Hydrochloride) | 1g Powder for Injection (IM/IV)Type I clear and colorless glass vial (Box of 1's) | Rx | Zeiss Pharmaceutical Pvt. Ltd.India | Baxter Healthcare Philippines Inc.Trader: Baxter Pharmaceuticals India Private Limited | DRP-6588 | Apr 18, 2028 | |
StafipimeCefepime (as hydrochloride) | 1 g Powder for Injection (IM/IV)USP Type III Colorless Glass Vial with rubber stopper and magenta flip-off seal x 10 mL + FFS Sterile Water for Injection (Box of 1's) | Rx | Inject Care Parenterals Pvt. Ltd.India | Marketzone Inc.Importer: Ambica International CorporationTrader: Stallion laboratories Pvt. Ltd. | DRP-3102 | Jul 12, 2029 | |
StarpimeCefepime (as hydrochloride) | 1 g Powder for injection (I.M./I/V.)USP Type III clear colorless glass vial (Box of 1's) | Rx | Celogen Pharma Pvt. Ltd.India | Pharmastar International Trading Corp. | DRP-7014 | Mar 4, 2031 | |
SupimeCefepime (as hydrochloride) | 1 g Powder for Injection (IM/IV)USP Type III Clear and Colorless Glass Vial x 20 mL (Box of 1’s) | Rx | Inject Care Parenterals Pvt. Ltd.India | Uni-Pharma Phils., Inc.Importer: Suhitas Pharmaceuticals Inc.Trader: Mac Heal Laboratories Ltd. | DRP-3266 | Sep 21, 2031 | |
SupimeCefepime (as hydrochloride) | 2 g Powder for Injection (IM/IV)20 mL-capacity USP Type 1 clear and colorless glass vial (Box of 1's) | Rx | Yeluri Formulations Pvt. Ltd.India | Importer: Suhitas Pharmaceuticals Inc.Trader: Sherrington Pharmaceuticals Pvt. Ltd. | DRP-3830 | Jul 9, 2027 | |
TerrapimeCefepime Hydrochloride | 2 g Powder for Injection (I.M./I.V.)USP Type I Clear Glass Vial x 20 mL (Box of 1's & 10's) | Rx | Yeluri Formulations Pvt. Ltd.India | Santerra TradingImporter: Medinova Pharmaceutical Inc. | DRP-3387-03 | Aug 9, 2028 | |
Totacef-1000Cefepime (as hydrochloride) (with L-Arginine) | 1 g Powder for Injection (I.M./I.V.)20 mL-capacity USP Type I clear and colorless glass vial with grey bromobutyl rubber stopper and aluminum seal with magenta flip-off cap (Box of 1's) | Rx | Mankind Pharma Limited (Unit-1)India | Ambica International Corporation | DRP-13716 | Mar 30, 2028 | |
UNIPIMCefepime (as hydrochloride) | 1 mg Powder for Injection (I.M./I.V.)15 mL USP Type I Clear Glass Vial + 10 mL Clear Glass Ampoule (Diluent) Water for Injection in Blister Tray Box of 1's | Rx | Drug International LimitedBangladesh | JAZMARK PHARMACEUTICAL | DR-XY42807 | Oct 14, 2028 | |
Unipime 1gCefepime (hydrochloride) | 1 g Powder for Injection (IV/IM)USP Type I Borosilicate Clear Glass Vial With Grey Chlorobutyl Rubber Stopper Sealed with Aluminum and Orange Flip Cap (Box of 10's); USP Type I Borosilicate Clear Glass Vial with Grey Chlorobutyl Rubber Stopper Sealed with Aluminum and Orange Flip Cap (Box of 1's) | Rx | Union Korea Pharm Co., Ltd.Republic of Korea | Uni-Pharma Phils., Inc.Importer: H & B Pharma International Inc. | DRP-9034 | Aug 13, 2030 | |
UrecefCefepime (as hydrochloride) | 2 g Powder for Injection (I.M./I.V.)USP Type II Glass Vial (Box of 10's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Endure Medical, Inc. | DR-XY45060 | Feb 11, 2031 | |
UrecefCefepime (as hydrochloride) | 500mg Powder for Injection (I.M./I.V.)USP Type II Clear Glass Vial Box of 10's | Rx | REYOUNG PHARMACEUTICAL CO., LTD.China | ENDURE MEDICAL, INC. | DR-XY46570 | May 21, 2029 | |
Welzpime 1000Cefepime (as hydrochloride) | 1g Powder for Injection (IM/IV)Type III Clear Glass Vial sealed with Rubber Stopper and Aluminum Seal with Green Flip-Off Cap x 1's + 10mL Sterile Water for Injection in LDPE Ampoule Box of 1's) | Rx | Malik Lifesciences Pvt. Ltd.India | SMHP Marketing & ConsultancyTrader: Unosource Pharma Ltd. | DRP-16917 | Aug 20, 2030 | |
ZEFAROXCefepime (as hydrochloride) | 1 g Powder for Injection (I.M./1.V.)Tubular glass vial, sealed with rubber stopper and capped with aluminium-plastics combination caps in monocarton Box of 10'S | Rx | CSPC Zhongnuo Pharmaceutical (Shijianzhuang) Co. Ltd.China | PhilRx Pharma Inc.Importer: AMB HK Enterprises Inc. | DRP-8376-02 | Sep 18, 2029 | |
ZefegenCefepime (as hydrochloride) | 1 g Powder for Injection (I.M./I.V)10 mL USP Type II glass vial with gray butyl rubber stopper, aluminum seal and blue flip-off cap (Box of 1's and 10's) | Rx | Reyoung Pharmaceutical Co. Ltd.China | GA2 Pharmaceutical Inc.Importer: Medinova Pharmaceutical Inc. | DRP-10999-01 | Dec 31, 2026 | |
ZepimCefepime (as hydrochloride) | 1 g powder for injectionUSP Type I colorless glass vial x 1's (Box of 1's) | Rx | Kyongbo Pharmaceutical Co., Ltd.Republic of Korea | PharmAsia-Cuvest, Incorporated | DR-XY41478 | Dec 18, 2027 | |
ZepimeCefepime (as Hydrochloride) | 1 g Powder for Injection (I.M./I.V.)Clear colorless glass vial with rubber stopper and light green flip-off aluminum seal (Box of 10's) | Rx | Singapore Pharmawealth Lifesciences, Inc.Philippines | — | DR-XY36676 | Sep 22, 2029 | |
1 g Powder for Injection (I.M./I.V.)1 g vial in individual boxes (Box of 10's) | Rx | Harbin Pharmaceutical Group Co., Ltd. General Pharm. FactoryChina | Phil. Pharmawealth, IncImporter: Endure Medical, Inc. | DRP-16400-01 | Feb 7, 2032 | ||
ZepimeCefepime (as Hydrochloride) | 2g Powder for Injection (I.M./I.V.)Clear colorless glass vial with light green flip-off seal (Box of 10's) | Rx | Singapore Pharmawealth Lifesciences, Inc.Philippines | — | DR-XY36674 | Sep 18, 2029 | |
ZepimeCefepime (as hydrochloride) | 500 mg Powder for Injection (I.M./I.V.)USP Type I Glass Vial with orange flip-off seal + 5 mL diluent Box of 1's | Rx | Singapore Pharmawealth Lifesciences, Inc.Philippines | — | DR-XY37533 | Jan 4, 2029 | |
1g Powder For Injection (IM/IV)Clear glass vial type III with grey butyl rubber stopper with blue flip-off aluminum cap (Box of 10's) | Rx | NCPC Hebei Huamin Pharmaceutical Company LimitedChina | Kwanstar Pharma Distributor | DRP-12418 | Aug 4, 2027 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS Cefepime for Injection, USP is a sterile white to pale yellow powder of cefepime in single-dose vials and it is available in the following strengths: 1 gram per vial 2 grams per vial Cefepime for Injection is a sterile powder of cefepime in single-dose vials for reconstitution, available in the following strengths: 1 gram per vial. (3) 2 grams per vial. (3)
Warnings/Precautions
- Hypersensitivity Reactions: Cross-hypersensitivity among beta-lactam antibacterial drugs may occur in up to 10% of patients with a history of penicillin allergy. If an allergic reaction to cefepime for injection occurs, discontinue the drug. (5.1)
- Neurotoxicity: May occur especially in patients with renal impairment administered unadjusted doses. If neurotoxicity associated with cefepime for injection therapy occurs, discontinue the drug. (5.2)
- Clostridioides difficile -Associated Diarrhea (CDAD): Evaluate if diarrhea occurs. (5.3)
5.1 Hypersensitivity Reactions
5.1 Hypersensitivity Reactions Before therapy with cefepime for injection is instituted, careful inquiry should be made to determine whether the patient has had previous immediate hypersensitivity reactions to cefepime, cephalosporins, penicillins, or other beta-lactams. Exercise caution if this product is to be given to penicillin-sensitive patients because cross-hypersensitivity among beta-lactam antibacterial drugs has been clearly documented and may occur in up to 10% of patients with a history of penicillin allergy.
If an allergic reaction to cefepime for injection occurs, discontinue the drug and institute appropriate supportive measures.
5.2 Neurotoxicity
5.2 Neurotoxicity Serious adverse reactions have been reported including life-threatening or fatal occurrences of the following: encephalopathy (disturbance of consciousness including confusion, hallucinations, stupor, and coma), aphasia, myoclonus, seizures, and nonconvulsive status epilepticus [see Adverse Reactions (6.2)]. Most cases occurred in patients with renal impairment who did not receive appropriate dosage adjustment.
However, some cases of neurotoxicity occurred in patients receiving a dosage adjustment appropriate for their degree of renal impairment. In the majority of cases, symptoms of neurotoxicity were reversible and resolved after discontinuation of cefepime and/or after hemodialysis. If neurotoxicity associated with cefepime therapy occurs, discontinue cefepime and institute appropriate supportive measures.
5.3 Clostridioides difficile
5.3 Clostridioides difficile -Associated Diarrhea Clostridioides difficile -associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including Cefepime for Injection, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.
C. difficile produces toxins A and B, which contribute to the development of CDAD. Hypertoxin-producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial drug use.
Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibacterial drug use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial drug treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.
5.4 Development of Drug-Resistant Bacteria
5.4 Development of Drug-Resistant Bacteria Prescribing cefepime for injection in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria. As with other antimicrobials, prolonged use of cefepime for injection may result in overgrowth of nonsusceptible microorganisms.
Repeated evaluation of the patient's condition is essential. Should superinfection occur during therapy, appropriate measures should be taken.
5.5 Drug/Laboratory Test Interactions Urinary Glucose
5.5 Drug/Laboratory Test Interactions Urinary Glucose The administration of cefepime may result in a false-positive reaction for glucose in the urine when using some methods (e.g. Clinitest TM tablets) [see Drug Interactions (7.1)]. Coombs' Tests Positive direct Coombs' tests have been reported during treatment with cefepime for injection.
In patients who develop hemolytic anemia, discontinue the drug and institute appropriate therapy. Positive Coombs' test may be observed in newborns whose mothers have received cephalosporin antibacterial drugs before parturition. Prothrombin Time Many cephalosporins, including cefepime, have been associated with a fall in prothrombin activity.
Those at risk include patients with renal or hepatic impairment, or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy. Prothrombin time should be monitored in patients at risk, and exogenous vitamin K administered as indicated.
Drug interactions
| Drug or class | Severity | Effect | What to do |
|---|---|---|---|
| Aminoglycosides; potent loop diuretics (furosemide) | Adjust or monitor | Nephrotoxicity reported with cephalosporins given with these drugs (label). | Monitor kidney function. |
Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.
renalcarematters.com, reviewed- Aminoglycosides: increased potential of nephrotoxicity and ototoxicity. Monitor renal function. (7.2)
- Diuretics: nephrotoxicity has been reported following concomitant administration of other cephalosporins with potent diuretics such as furosemide. Monitor renal function. (7.3)
7.1 Drug/Laboratory Test Interactions
7.1 Drug/Laboratory Test Interactions The administration of cefepime may result in a false-positive reaction for glucose in the urine with certain methods. It is recommended that glucose tests based on enzymatic glucose oxidase reactions be used.
7.2 Aminoglycosides
7.2 Aminoglycosides Monitor renal function if aminoglycosides are to be administered with cefepime for injection because of the increased potential of nephrotoxicity and ototoxicity of aminoglycoside antibacterial drugs.
7.3 Diuretics
7.3 Diuretics Nephrotoxicity has been reported following concomitant administration of other cephalosporins with potent diuretics such as furosemide. Monitor renal function when cefepime is concomitantly administered with potent diuretics.
Adverse reactions
Common
- Local infusion reactions
- Positive Coombs test
- Low phosphorus; raised ALT, AST, PT and PTT
- Rash
Serious
- Neurotoxicity: encephalopathy, myoclonus, seizures, nonconvulsive status epilepticus (mainly unadjusted doses in kidney impairment)
- Anaphylaxis (cross-reactivity with penicillins up to 10%)
- Clostridioides difficile-associated diarrhea
- The following adverse reactions are discussed in the Warnings and Precautions section and below: Hypersensitivity Reactions [see Warnings and Precautions (5.1)] Neurotoxicity [see Warnings and Precautions (5.2)] Clostridioides difficile -Associated Diarrhea [see Warnings and Precautions (5.3)] The most common adverse reactions (incidence ≥ 1%) were local reactions, positive Coombs' test, decreased phosphorous, increased ALT and AST, increased PT and PTT and rash. (6.1)
- At the highest dose (2 g every 8 hours), incidence of adverse reactions was ≥1% for rash, diarrhea, nausea, vomiting, pruritus, fever, and headache. (6.1)
- To report SUSPECTED ADVERSE REACTIONS, contact Sagent Pharmaceuticals at 1-866-625-1618 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience
6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In clinical trials using multiple doses of cefepime, 4137 patients were treated with the recommended dosages of cefepime (500 mg to 2 g intravenous every 12 hours).
There were no deaths or permanent disabilities thought related to drug toxicity. Sixty-four (1.5%) patients discontinued medication due to adverse reactions. Thirty-three (51%) of these 64 patients who discontinued therapy did so because of rash. The percentage of cefepime-treated patients who discontinued study drug because of drug-related adverse reactions was similar at daily doses of 500 mg, 1 g, and 2 g every 12 hours (0.8%, 1.1%, and 2%, respectively).
However, the incidence of discontinuation due to rash increased with the higher recommended doses. The following adverse reactions (Table 5) were identified in clinical trials conducted in North America (n=3125 cefepime-treated patients). Table 5: Adverse Reactions in Cefepime Multiple-Dose Dosing Regimens Clinical Trials in North America Incidence equal to or greater than 1% Local adverse reactions (3%), including phlebitis (1.3%), pain and/or inflammation (0.6%)*; rash (1.1%) Incidence less than 1% but greater than 0.1% Colitis (including pseudomembranous colitis), diarrhea, erythema, fever, headache, nausea, oral moniliasis, pruritus, urticaria, vaginitis, vomiting, anemia At the higher dose of 2 g every 8 hours, the incidence of adverse reactions was higher among the 795 patients who received this dose of cefepime.
They consisted of rash (4%), diarrhea (3%), nausea (2%), vomiting (1%), pruritus (1%), fever (1%), and headache (1%). The following (Table 6) adverse laboratory changes, with cefepime, were seen during clinical trials conducted in North America. Table 6: Adverse Laboratory Changes in Cefepime Multiple-Dose Dosing Regimens Clinical Trials in North America * Hypocalcemia was more common among elderly patients.
Clinical consequences from changes in either calcium or phosphorus were not reported. Incidence equal to or greater than 1% Positive Coombs' test (without hemolysis) (16.2%); decreased phosphorus (2.8%); increased Alanine Transaminase (ALT) (2.8%), Aspartate Transaminase (AST) (2.4%), eosinophils (1.7%); abnormal PTT (1.6%), Prothrombin Time (PT) (1.4%) Incidence less than 1% but greater than 0.1% Increased alkaline phosphatase, Blood Urea Nitrogen (BUN), calcium, creatinine, phosphorus, potassium, total bilirubin; decreased calcium*, hematocrit, neutrophils, platelets, White Blood Cells (WBC) A similar safety profile was seen in clinical trials of pediatric patients.
6.2 Postmarketing Experience
6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of cefepime for injection. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
In addition to the adverse reactions reported during the North American clinical trials with cefepime, the following adverse reactions have been reported during worldwide postmarketing experience. Encephalopathy (disturbance of consciousness including confusion, hallucinations, stupor, and coma), aphasia, myoclonus, seizures, and nonconvulsive status epilepticus have been reported [see Warnings and Precautions (5.2)].
Anaphylaxis including anaphylactic shock, transient leukopenia, neutropenia, agranulocytosis and thrombocytopenia, have been reported.
6.3 Cephalosporin-Class Adverse Reactions
6.3 Cephalosporin-Class Adverse Reactions In addition to the adverse reactions listed above that have been observed in patients treated with cefepime, the following adverse reactions and altered laboratory tests have been reported for cephalosporin-class antibacterial drugs: Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis, renal dysfunction, toxic nephropathy, aplastic anemia, hemolytic anemia, hemorrhage, hepatic dysfunction including cholestasis, and pancytopenia.
Adverse reaction frequency tables (US label) US FDA label
| Incidence equal to or greater than 1% | Local adverse reactions (3%), including phlebitis (1.3%), pain and/or inflammation (0.6%)*; rash (1.1%) |
| Incidence less than 1% but greater than 0.1% | Colitis (including pseudomembranous colitis), diarrhea, erythema, fever, headache, nausea, oral moniliasis, pruritus, urticaria, vaginitis, vomiting, anemia |
| * Hypocalcemia was more common among elderly patients. Clinical consequences from changes in either calcium or phosphorus were not reported. | |
| Incidence equal to or greater than 1% | Positive Coombs' test (without hemolysis) (16.2%); decreased phosphorus (2.8%); increased Alanine Transaminase (ALT) (2.8%), Aspartate Transaminase (AST) (2.4%), eosinophils (1.7%); abnormal PTT (1.6%), Prothrombin Time (PT) (1.4%) |
| Incidence less than 1% but greater than 0.1% | Increased alkaline phosphatase, Blood Urea Nitrogen (BUN), calcium, creatinine, phosphorus, potassium, total bilirubin; decreased calcium*, hematocrit, neutrophils, platelets, White Blood Cells (WBC) |
Monitoring parameters
- CrCl for dose; neurotoxicity (encephalopathy, myoclonus, seizures, nonconvulsive status epilepticus), mainly with unadjusted doses in kidney impairment; stop cefepime if it occurs (label 5.2). Kidney function with aminoglycosides or loop diuretics. Kidney
- CrCl for dose
- Mental status and neurologic signs, especially in kidney impairment
- Kidney function with aminoglycosides or loop diuretics
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary There are no cases of cefepime exposure during pregnancy reported from postmarketing experience or from clinical trials. Available data from published observational studies and case reports over several decades with cephalosporin use in pregnant women have not established drug-associated risks of major birth defects, miscarriage or adverse maternal or fetal outcomes (see Data).
Cefepime was not associated with adverse developmental outcomes in rats, mice, or rabbits when administered parenterally during organogenesis. The doses used in these studies were 1.6 (rats), approximately equal to (mice), and 0.3 times (rabbits) the recommended maximum human dose (see Data). The estimated background risk of major birth defects and miscarriage for the indicated population is unknown.
All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Human Data While available studies cannot definitively establish the absence of risk, published data from case-control studies and case reports over several decades have not identified an association with cephalosporin use during pregnancy and major birth defects, miscarriage, or other adverse maternal or fetal outcomes.
Available studies have methodologic limitations, including small sample size, retrospective data collection, and inconsistent comparator groups. Animal Data Cefepime was not embryocidal and did not cause fetal malformations when administered parenterally during the period of organogenesis to rats at doses up to 1000 mg/kg/day, to mice at doses up to 1200 mg/kg/day, or to rabbits at doses up to 100 mg/kg/day.
These doses are 1.6 times (rats), approximately equal to (mice), and 0.3 times (rabbits) the maximum recommended clinical dose based on body surface area.
Mechanism of action
12.1 Mechanism of Action Cefepime is a cephalosporin antibacterial drug [see Microbiology (12.4)].
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics Similar to other beta-lactam antimicrobial agents, the time that the unbound plasma concentration of cefepime exceeds the MIC of the infecting organism has been shown to best correlate with efficacy in animal models of infection. However, the pharmacokinetic/pharmacodynamics relationship for cefepime has not been evaluated in patients.
Pharmacokinetics
Key PK parameters
| Bioavailability | IM: completely absorbed |
|---|---|
| Half-life | About 2 hours |
| Half-life in kidney failure (ESKD) kidney | 13.5 hours on hemodialysis; 19 hours on continuous peritoneal dialysis (label) |
| Volume of distribution | About 18 L |
| Protein binding | About 20% |
| Renal excretion kidney | Mainly renal; clearance falls in proportion to CrCl (label) |
| Dialyzability kidney | Yes (about 68% per 3-hour hemodialysis) |
Elimination of cefepime is principally via renal excretion with an average (±SD) half-life of 2 (±0.3) hours and total body clearance of 120 (±8) mL/min in healthy volunteers.
Metabolism and Excretion Cefepime is metabolized to N-methylpyrrolidine (NMP) which is rapidly converted to the N-oxide (NMP-N-oxide).
Urinary recovery of unchanged cefepime accounts for approximately 85% of the administered dose.
Because renal excretion is a significant pathway of elimination, patients with renal dysfunction and patients undergoing hemodialysis require dosage adjustment [see Dosage and Administration ( 2.3 )] .
The average half-life in patients requiring hemodialysis was 13.5 (±2.7) hours and in patients requiring continuous peritoneal dialysis was 19 (±2) hours.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Pharmacokinetic parameters for cefepime in healthy adult male volunteers (n=9) following single 30-minute infusions (IV) of cefepime 500 mg, 1 g, and 2 g are summarized in Table 7. Elimination of cefepime is principally via renal excretion with an average (±SD) half-life of 2 (±0.3) hours and total body clearance of 120 (±8) mL/min in healthy volunteers.
Cefepime pharmacokinetics are linear over the range 250 mg to 2 g. There is no evidence of accumulation in healthy adult male volunteers (n=7) receiving clinically relevant doses for a period of 9 days. Table 7: Mean Pharmacokinetic Parameters for Cefepime (±SD), Intravenous Administration Cefepime for Injection Parameter 500 mg IV 1 g IV 2 g IV C max, mcg/mL 39.1 (3.5) 81.7 (5.1) 163.9 (25.3) AUC, h•mcg/mL 70.8 (6.7) 148.5 (15.1) 284.8 (30.6) Number of subjects (male) 9 9 9 Pharmacokinetic parameters for cefepime following a single intramuscular injection are summarized in Table 8.
The pharmacokinetics of cefepime are linear over the range of 500 mg to 2 g intramuscularly and do not vary with respect to treatment duration. Table 8: Mean Pharmacokinetic Parameters for Cefepime (±SD), Intramuscular Administration Cefepime for Injection Parameter 500 mg IM 1 g IM 2 g IM C max, mcg/mL 13.9 (3.4) 29.6 (4.4) 57.5 (9.5) T max, h 1.4 (0.9) 1.6 (0.4) 1.5 (0.4) AUC, h•mcg/mL 60 (8) 137 (11) 262 (23) Number of subjects (male) 6 6 12 Absorption Following intramuscular (IM) administration, cefepime is completely absorbed.
Distribution The average steady-state volume of distribution of cefepime is 18 (±2) L. The serum protein binding of cefepime is approximately 20% and is independent of its concentration in serum. Concentrations of cefepime achieved in specific tissues and body fluids are listed in Table 9. Table 9: Mean Concentrations of Cefepime in Specific Body Fluids (mcg/mL) or Tissues (mcg/g) Tissue or Fluid Dose/ Route # of Patients Mean Time of Sample Post-Dose (h) Mean Concentration Blister Fluid 2 g IV 6 1.5 81.4 mcg/mL Bronchial Mucosa 2 g IV 20 4.8 24.1 mcg/g Sputum 2 g IV 5 4 7.4 mcg/mL Urine 500 mg IV 1 g IV 2 g IV 8 12 12 0 to 4 0 to 4 0 to 4 292 mcg/mL 926 mcg/mL 3120 mcg/mL Bile 2 g IV 26 9.4 17.8 mcg/mL Peritoneal Fluid 2 g IV 19 4.4 18.3 mcg/mL Appendix 2 g IV 31 5.7 5.2 mcg/g Gallbladder 2 g IV 38 8.9 11.9 mcg/g Prostate 2 g IV 5 1 31.5 mcg/g Data suggest that cefepime does cross the inflamed blood-brain barrier.
The clinical relevance of these data is uncertain at this time. Metabolism and Excretion Cefepime is metabolized to N-methylpyrrolidine (NMP) which is rapidly converted to the N-oxide (NMP-N-oxide). Urinary recovery of unchanged cefepime accounts for approximately 85% of the administered dose. Less than 1% of the administered dose is recovered from urine as NMP, 6.8% as NMP-N-oxide, and 2.5% as an epimer of cefepime.
Because renal excretion is a significant pathway of elimination, patients with renal dysfunction and patients undergoing hemodialysis require dosage adjustment [see Dosage and Administration (2.3)]. Specific Populations Patients with Renal impairment Cefepime pharmacokinetics have been investigated in patients with various degrees of renal impairment (n=30).
The average half-life in patients requiring hemodialysis was 13.5 (±2.7) hours and in patients requiring continuous peritoneal dialysis was 19 (±2) hours. Cefepime total body clearance decreased proportionally with creatinine clearance in patients with abnormal renal function, which serves as the basis for dosage adjustment recommendations in this group of patients [see Dosage and Administration (2.3)].
Patients with Hepatic impairment The pharmacokinetics of cefepime were unaltered in patients with hepatic impairment who received a single 1 g dose (n=11). Geriatric patients Cefepime pharmacokinetics have been investigated in elderly (65 years of age and older) men (n=12) and women (n=12) whose mean (SD) creatinine clearance was 74 (±15) mL/min.
There appeared to be a decrease in cefepime total body clearance as a function of creatinine clearance. Therefore, dosage administration of cefepime in the elderly should be adjusted as appropriate if the patient's creatinine clearance is 60 mL/min or less [see Dosage and Administration (2.3)]. Pediatric patients Cefepime pharmacokinetics have been evaluated in pediatric patients from 2 months to 11 years of age following single and multiple doses on every 8 hours (n=29) and every 12 hours (n=13) schedules.
Following a single intravenous dose, total body clearance and the steady-state volume of distribution averaged 3.3 (±1) mL/min/kg and 0.3 (±0.1) L/kg, respectively. The urinary recovery of unchanged cefepime was 60.4 (±30.4)% of the administered dose, and the average renal clearance was 2 (±1.1) mL/min/kg. There were no significant effects of age or gender (25 male vs. 17 female) on total body clearance or volume of distribution, corrected for body weight.
No accumulation was seen when cefepime was given at 50 mg per kg every 12 hours (n=13), while C max, AUC, and t ½ were increased about 15% at steady state after 50 mg per kg every 8 hours. The exposure to cefepime following a 50 mg per kg intravenous dose in a pediatric patient is comparable to that in an adult treated with a 2 g intravenous dose.
The absolute bioavailability of cefepime after an intramuscular dose of 50 mg per kg was 82.3 (±15)% in eight patients.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Cefepime 1 g Vial | ₱58.98–₱280.00Reference ₱84.38 | per vial | DPRI procurement range |
| Cefepime 2 g Vial | ₱193.33–₱245.33Reference ₱193.33 | per vial | DPRI procurement range |
| Cefepime 500 mg Vial | ₱65.34–₱144.00Reference ₱112.33 | per vial | DPRI procurement range |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Cefepime (as hydrochloride) |
| PNF listing | Inj.: 500 mg, 1 g and 2 g vial (IM, IV)Restrictions: Reserve antimicrobial (PNF) |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. cefepime · Sagent Pharmaceuticals [US FDA-approved label, version 24, August 3, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de477f37-40f6-4295-ae72-a2ee36a8922e
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
- Sagent Pharmaceuticals. (2026). Cefepime for injection, USP [Prescribing information; US FDA-approved label, ANDA065441, set ID de477f37-40f6-4295-ae72-a2ee36a8922e, version effective August 3, 2026]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de477f37-40f6-4295-ae72-a2ee36a8922e
- Li, L., Li, X., Xia, Y., Chu, Y., Zhong, H., Li, J., Liang, P., Bu, Y., Zhao, R., Liao, Y., Yang, P., Lu, X., & Jiang, S. (2020). Recommendation of antimicrobial dosing optimization during continuous renal replacement therapy. Frontiers in Pharmacology, 11, Article 786. https://doi.org/10.3389/fphar.2020.00786
- Li, P. K.-T., Chow, K. M., Cho, Y., Fan, S., Figueiredo, A. E., Harris, T., Kanjanabuch, T., Kim, Y.-L., Madero, M., Malyszko, J., Mehrotra, R., Okpechi, I. G., Perl, J., Piraino, B., Runnegar, N., Teitelbaum, I., Wong, J. K.-W., Yu, X., & Johnson, D. W. (2022). ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment. Peritoneal Dialysis International, 42(2), 110–153. https://doi.org/10.1177/08968608221080586
- Tsai, Y. V., Soto, C., Crawford, G., & Dzintars, K. (2025). Important antimicrobial dosing considerations for transitions of care: Focus on thrice-weekly dosing in hemodialysis. American Journal of Health-System Pharmacy, 82(4), 203–210. https://doi.org/10.1093/ajhp/zxae259
renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.
Last updated: .


